

Special Issue

Monoclonal Antibody Research in the Era of COVID-19

Message from the Guest Editor

A monoclonal antibody is an antibody originating from a unique B cell lineage, binding only to the same epitope with high affinity for its target. Over the years, monoclonal antibodies have been used or heavily investigated for their potential role against many diseases, including bacterial and viral infection and cancer. Likewise, antibody-based therapy alone or in combination with other treatments has been demonstrated to be effective for both the early and late stages of SARS-COV-2 infection in the past three years. In this Special Issue, we invite reviews, research papers, and clinical trial applications elaborating on mechanisms whereby monoclonal antibodies act directly and indirectly against various SARS-COV-2 variants and developing strategies and technologies for antibody engineering related to COVID-19 to enhance immune protection. Additionally, new combinations of multiple monoclonal antibodies targeting different antigens or bispecific antibodies to overcome the viral escape phenomenon are of interest.

Guest Editor

Dr. Miaomiao Shi

Missiakas-Schneewind Lab, University of Chicago, Building 204 9700
S. Cass Avenue, Lemont, IL 60439, USA

Deadline for manuscript submissions

closed (1 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/154019

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/

[vaccines](https://vaccines.mdpi.com)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).